Processa Pharmaceuticals Current Ratio Growth & History (PCSA)
Processa Pharmaceuticals's current ratio was 2.54 for fiscal 2025.
View full Processa Pharmaceuticals company overviewProcessa Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.54 | 1.31 | +106.83% |
| 2024 | 2024-12-31 | 1.23 | −6.48 | −84.10% |
| 2023 | 2023-12-31 | 7.71 | −0.69 | −8.21% |
| 2022 | 2022-12-31 | 8.40 | −10.48 | −55.50% |
| 2021 | 2021-12-31 | 18.87 | 5.60 | +42.23% |
| 2020 | 2020-12-31 | 13.27 | 12.43 | +1470.06% |
| 2019 | 2019-12-31 | 0.85 | −2.28 | −72.99% |
| 2018 | 2018-12-31 | 3.13 | 1.99 | +175.60% |
| 2017 | 2017-12-31 | 1.14 | −22.79 | −95.25% |
| 2016 | 2016-12-31 | 23.92 | 23.87 | +47741.51% |
| 2015 | 2015-12-31 | 0.05 | −0.40 | −88.98% |
| 2014 | 2014-12-31 | 0.45 | −0.00 | −1.08% |
| 2013 | 2013-12-31 | 0.46 | −1.16 | −71.62% |
| 2012 | 2012-12-31 | 1.62 | — | — |
Processa Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.87 | −2.58 | −74.89% |
| Q1 2026 | 2026-03-31 | 0.98 | −1.95 | −66.58% |
| Q4 2025 | 2025-12-31 | 2.54 | 1.31 | +106.83% |
| Q3 2025 | 2025-09-30 | 3.76 | −0.21 | −5.20% |
| Q2 2025 | 2025-06-30 | 3.45 | −1.37 | −28.45% |
| Q1 2025 | 2025-03-31 | 2.93 | −6.77 | −69.79% |
| Q4 2024 | 2024-12-31 | 1.23 | −6.48 | −84.10% |
| Q3 2024 | 2024-09-30 | 3.97 | −5.60 | −58.54% |
| Q2 2024 | 2024-06-30 | 4.82 | −7.23 | −60.00% |
| Q1 2024 | 2024-03-31 | 9.70 | 4.04 | +71.48% |
| Q4 2023 | 2023-12-31 | 7.71 | −0.69 | −8.21% |
| Q3 2023 | 2023-09-30 | 9.57 | 0.44 | +4.87% |
| Q2 2023 | 2023-06-30 | 12.05 | 3.16 | +35.59% |
| Q1 2023 | 2023-03-31 | 5.65 | −9.83 | −63.49% |
| Q4 2022 | 2022-12-31 | 8.40 | −10.48 | −55.50% |
| Q3 2022 | 2022-09-30 | 9.13 | −7.73 | −45.84% |
| Q2 2022 | 2022-06-30 | 8.89 | −10.55 | −54.27% |
| Q1 2022 | 2022-03-31 | 15.49 | −6.91 | −30.86% |
| Q4 2021 | 2021-12-31 | 18.87 | 5.60 | +42.23% |
| Q3 2021 | 2021-09-30 | 16.85 | 16.71 | +11817.45% |
| Q2 2021 | 2021-06-30 | 19.43 | 19.13 | +6294.09% |
| Q1 2021 | 2021-03-31 | 22.40 | 22.12 | +7731.56% |
| Q4 2020 | 2020-12-31 | 13.27 | 12.43 | +1470.06% |
| Q3 2020 | 2020-09-30 | 0.14 | −2.35 | −94.31% |
| Q2 2020 | 2020-06-30 | 0.30 | −0.96 | −75.95% |
| Q1 2020 | 2020-03-31 | 0.29 | −1.84 | −86.56% |
| Q4 2019 | 2019-12-31 | 0.85 | −2.28 | −72.99% |
| Q3 2019 | 2019-09-30 | 2.49 | −1.57 | −38.65% |
| Q2 2019 | 2019-06-30 | 1.26 | −4.27 | −77.16% |
| Q1 2019 | 2019-03-31 | 2.13 | 1.48 | +228.85% |
| Q4 2018 | 2018-12-31 | 3.13 | 1.99 | +175.60% |
| Q3 2018 | 2018-09-30 | 4.05 | 3.36 | +482.29% |
| Q2 2018 | 2018-06-30 | 5.53 | 5.53 | +707550.40% |
| Q1 2018 | 2018-03-31 | 0.65 | 0.65 | +96237.90% |
| Q4 2017 | 2017-12-31 | 1.14 | −22.79 | −95.25% |
| Q3 2017 | 2017-09-30 | 0.70 | 0.68 | +4413.39% |
| Q2 2017 | 2017-06-30 | 0.00 | −0.02 | −96.02% |
| Q1 2017 | 2017-03-31 | 0.00 | −0.02 | −96.93% |
| Q4 2016 | 2016-12-31 | 23.92 | 23.87 | +47741.51% |
| Q3 2016 | 2016-09-30 | 0.02 | −0.14 | −90.02% |
| Q2 2016 | 2016-06-30 | 0.02 | −0.21 | −91.42% |
| Q1 2016 | 2016-03-31 | 0.02 | −0.27 | −92.43% |
| Q4 2015 | 2015-12-31 | 0.05 | −0.40 | −88.98% |
| Q3 2015 | 2015-09-30 | 0.15 | −0.34 | −68.78% |
| Q2 2015 | 2015-06-30 | 0.23 | −0.60 | −72.41% |
| Q1 2015 | 2015-03-31 | 0.29 | −0.32 | −52.64% |
| Q4 2014 | 2014-12-31 | 0.45 | −0.00 | −1.08% |
| Q3 2014 | 2014-09-30 | 0.49 | −0.51 | −50.65% |
| Q2 2014 | 2014-06-30 | 0.83 | 0.43 | +109.22% |
| Q1 2014 | 2014-03-31 | 0.61 | — | — |
| Q4 2013 | 2013-12-31 | 0.46 | −1.16 | −71.62% |
| Q3 2013 | 2013-09-30 | 1.00 | — | — |
| Q2 2013 | 2013-06-30 | 0.40 | — | — |
| Q4 2012 | 2012-12-31 | 1.62 | — | — |
Processa Pharmaceuticals current ratio trends
Over the last five fiscal years, Processa Pharmaceuticals's current ratio decreased from 13.27 to 2.54, a change of −10.73. The latest reported quarter, Q2 2026, shows 0.87.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Processa Pharmaceuticals source filings ↗